Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: To evaluate the performance of the iStar high-sensitivity cardiac troponin I (hs-cTnI) assay, focusing on its sensitivity, precision, linearity, and consistency with plasma samples, and to establish sex-specific 99th percentile upper reference limits.

Methods: The iStar hs-cTnI assay was assessed using the Drawray iStar 500 analyzer. Key performance metrics such as the limits of blank (LoB), detection (LoD) and quantitation (LoQ), precision, linearity, and agreement between sample types were evaluated according to Clinical and Laboratory Standards Institute (CLSI) guidelines. A methodological comparison was performed with the Abbott ARCHITECT hs-cTnI assay, and cross-reactivity with others troponins was assessed.

Results: The iStar hs-cTnI assay demonstrated robust sensitivity with a LoB of 0.09 ng/L and LoD of 0.31 ng/L. The LoQ was 0.79 ng/L for 20 % coefficient of variation (CV) and 1.85 ng/L for 10 % CV. Precision testing revealed CVs of 1.4-4.8 % near the 99th percentile upper reference limit (URL). The assay exhibited excellent linearity (r=1.00) and high agreement between whole blood and plasma samples (slope=0.936). Methodological comparison with the Abbott ARCHITECT hs-cTnI showed a high correlation coefficient of 0.983. Cross-reactivity with skeletal muscle troponin I, cardiac troponin C, and cardiac troponin T was negligible. In healthy individuals, the overall 99th percentile URL was 16 ng/L, with sex-specific values of 18 ng/L for males and 14 ng/L for females.

Conclusions: The iStar hs-cTnI assay demonstrates high sensitivity and precision, supporting it suitable for the rapid diagnosis of acute myocardial infarction using whole blood samples. Its high agreement with plasma and established sex-specific URL support its potential for clinical use in acute coronary syndrome management.

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm-2025-0143DOI Listing

Publication Analysis

Top Keywords

hs-ctni assay
20
cardiac troponin
16
99th percentile
12
istar hs-ctni
12
high-sensitivity cardiac
8
sensitivity precision
8
precision linearity
8
plasma samples
8
percentile upper
8
upper reference
8

Similar Publications

Atherosclerotic cardiovascular disease remains one of the leading causes of morbidity and mortality worldwide, accounting for approximately 3.9 million deaths annually due to its complications. This single-center, retrospective cohort study included 109 patients who underwent coronary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) between April and July 2022 at the Cardiology Clinic of the County Emergency Clinical Hospital in Targu Mureș, Romania.

View Article and Find Full Text PDF

This study aimed to investigate the association between serum high-sensitivity cardiac troponin I (hs-cTnI) concentrations, platelet counts, and the severity of neonatal hyperbilirubinemia (NHB), as well as their correlation with the total bilirubin/albumin (B/A) ratio. A total of 82 neonates diagnosed with NHB and treated at JingMen People's Hospital of Hubei Province, China, between September 2023 and December 2023 were enrolled. Participants were categorized into mild and severe NHB groups based on total bilirubin levels.

View Article and Find Full Text PDF

Introduction: In Malaysia, acute coronary syndrome is the leading cause of hospitalisation. Identification of patients with low 30-day risk of major adverse cardiac event (MACE) may facilitate an early and safe discharge from overcrowding emergency departments (ED). This study aimed to determine the diagnostic accuracy of high-sensitivity-cardiac-troponin-I (hs-cTnI) for ruling out 30-day MACE among chest pain patients in ED.

View Article and Find Full Text PDF

Background: No therapy is approved for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The ODYSSEY-HCM (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [ODYSSEY-HCM]; NCT05582395) trial, the largest to date in patients with hypertrophic cardiomyopathy (HCM), evaluating the efficacy of mavacamten in symptomatic adults with nHCM, did not demonstrate improvements in its primary endpoints (functional capacity and patient-reported health status).

Objectives: The current exploratory analysis from the ODYSSEY-HCM trial reports the associations between: 1) baseline biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP] and high-sensitivity cardiac troponin I [cTnI]) with clinical, exercise, and echocardiographic characteristics; and 2) comparing changes in these biomarkers from baseline to week 48 between mavacamten and placebo groups.

View Article and Find Full Text PDF

Objectives: Cardiac troponins (cTn) are used to detect and quantify acute cardiomyocyte injury. In patients presenting with symptoms that could indicate myocarditis, elevated cTn concentrations typically mandate cardiac catheterization and heart muscle biopsy or cardiac magnetic resonance imaging (CMR). Accordingly, increased cTn levels due to macrotroponin - a complex between patient anti-troponin autoantibodies and cTn - could lead to unnecessary and potentially harmful interventions.

View Article and Find Full Text PDF